MIT’s Generative Model for Protein Drugs: Faster Design, New Validation Burden

MIT researchers reported a generative AI model for protein-based drug design that predicts synthetic protein folding and interactions with targets, aiming to reduce wet-lab trial-and-error. The work is positioned as enabling more “programmable” drug discovery and lowering R&D cost by shifting optimization into computation.